Daiwa Securities Group Inc. lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 50.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 37,802 shares of the life sciences company's stock after selling 38,256 shares during the period. Daiwa Securities Group Inc.'s holdings in Illumina were worth $5,051,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in ILMN. WCM Investment Management LLC increased its stake in shares of Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after buying an additional 867,673 shares during the period. ARK Investment Management LLC purchased a new position in shares of Illumina during the fourth quarter valued at $91,714,000. Massachusetts Financial Services Co. MA increased its stake in shares of Illumina by 148.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company's stock valued at $137,735,000 after buying an additional 631,294 shares during the period. Janus Henderson Group PLC increased its stake in shares of Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock valued at $282,735,000 after buying an additional 625,245 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Illumina by 116.9% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company's stock valued at $115,663,000 after buying an additional 466,519 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.
Illumina Trading Down 0.4 %
Illumina stock opened at $84.20 on Thursday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 52 week low of $80.18 and a 52 week high of $156.66. The company has a market capitalization of $13.34 billion, a price-to-earnings ratio of -10.96, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The stock has a 50-day moving average price of $115.46 and a 200 day moving average price of $130.52.
Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages have recently commented on ILMN. Barclays restated an "underweight" rating on shares of Illumina in a research note on Tuesday. Morgan Stanley cut their target price on Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 11th. Stephens reiterated an "overweight" rating and issued a $156.00 target price on shares of Illumina in a research note on Tuesday. Citigroup cut their target price on Illumina from $130.00 to $90.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Finally, Piper Sandler lifted their target price on Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $140.90.
View Our Latest Report on ILMN
Illumina Company Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
